JAMA Author Interviews Risankizumab for Ulcerative Colitis
Jul 22, 2024
Guest Gilaad G. Kaplan discusses Risankizumab for ulcerative colitis with JAMA Editor. Topics include personalized therapy with monoclonal antibodies targeting IL-23 pathway, phase 3 trial results showing higher remission rates, complexities in comparing risankizumab to placebo, and the importance of precision medicine in treatment strategies.
Chapters
Transcript
Episode notes
1 2 3 4 5
Intro
00:00 • 4min
Monoclonal Antibodies Targeting IL-23 in Ulcerative Colitis Treatment
04:19 • 2min
Study on Risankizumab for Ulcerative Colitis
06:12 • 3min
Comparing Risankizumab to Placebo and Sequencing Therapies for Ulcerative Colitis
09:18 • 2min
Exploring Treatment Options and Precision Medicine for Ulcerative Colitis
11:40 • 4min